BioKnow: A 6-year analysis reveals COVID Backlogs, manufacture facilities, and a biologics pivot
They let pharma companies redeem their drug applications. They make us aware of why access to new treatments are delayed. They surge and sink stock prices.
They are complete response letters (CRLs).
A CRL is a formal notice issued by the USFDA to inform a drug developer that their regulatory submission, either a New Drug Application (NDA) or Biologics License Application (BLA), cannot be approved in its current form and the reasons why.
The monthly distribution of FDA CRL release dates from 2020-2025.
Historically, CRLs were not released publicly as they contained confidential information regarding commercial processes, proprietary manufacturing data, and trade secrets. Following RFK Jr’s push for “radical transparency” by the FDA, the FDA has maintained an updated repository of redacted CRLs since July 2025. Reception to these changes were generally positive because:
Patients and doctors can better understand why access to new treatments is delayed.
Investors can better understand the financial risk of a company’s drug pipeline,
Litigators can prove that a company’s executives’ actions intended to deceive investors.
The industry may assume that CRLs are released relatively evenly throughout the year. However, an analysis of CRL publication times reveals several emerging trends:
More BLA applications: Companies are heavily prioritizing large-molecule biologics, cell and gene therapies, and biosimilars because they command higher price points, target highly profitable rare disease markets, and offer stronger defenses against generic competition.
CRLs for BLAs released later than NDAs: From 2020-2025, the first, second, and third quartiles occur later for BLAs than NDAs – potentially because manufacture, characterisation, and pre-approval inspections of manufacturing facilities are more complicated for biologics.
CRLs were fewer and released earlier in 2022-2023: The 2020-2021 period was heavily disrupted by the pandemic; the FDA was forced to pause routine facility inspections and divert massive resources to COVID-19 vaccines and therapeutics, delaying drug reviews to 2022-2023.
Follow Nimit Mistry on LinkedIn
Win one of 5 tickets to the Galien Forum!
October 29, 2026 — New York City 🗽🇺🇸
We’re giving away 5 passes to the Galien Forum, and if you have ever wanted to be in a room with the people leading some of the most influential companies in pharma, this is your opportunity.
Taking place on October 29, 2026, in New York City, the Galien Forum brings together global chairs, senior executives, scientists, innovators and decision-makers for meaningful conversations about the ideas shaping the future of medicine and healthcare.Attendees will have the opportunity to hear from and connect with leaders from Johnson & Johnson, Pfizer, Roche, Regeneron, Merck and other globally recognized organizations.
These are the people operating at the cutting edge of the industry developing new treatments, advancing scientific research, building breakthrough technologies and making the decisions that influence the direction of the pharmaceutical industry at large.
For more than 20 years, Prix Galien USA has recognized the innovations transforming patient care. The Galien Forum creates an opportunity to go beyond the awards and hear directly from the leaders, researchers and organizations behind that progress.
You can see the post HERE!
Follow The Galien Foundation on LinkedIn to stay updated on announcements, speakers, and innovations and upcoming event.
How a WHO Maturity Level 3 rating is re-energizing Egypt’s pharma industry
Egyptian Prime Minister Mostafa Madbouly is prioritizing the domestic production of pharmaceuticals and medical supplies to reduce import dependence, secure local market needs, and expand export opportunities. Under Chairman Ali Al-Ghamrawy, the Egyptian Drug Authority (EDA) attained WHO Maturity Level 3 for regulating medicines. Following the same accreditation for vaccines in March 2022, Egypt is the first African country to achieve this dual recognition.
Beyond Maturity Level 3, the EDA’s pharmaceutical control laboratories have recently secured WHO prequalification. The authority is now actively implementing upgrades and passing reassessments to eventually reach WHO-accredited Maturity Level 4. The WHO recognition allows Egypt to actively participate in shaping global pharmaceutical policies and standards while solidifying its leadership position across Arab and African markets.
Maintaining WHO Maturity Level 3 for both medicines and vaccines confirms that Egypt's regulatory framework operates efficiently and consistently aligns with strict international benchmarks. By pushing to localize medical-supply manufacturing, the government is treating the pharmaceutical sector as a strategic national priority to ensure long-term public health security and bolster economic resilience.
How are Nordic CEOs turning a small region into a biotech powerhouse?
CEOs from BioArctic, AlzeCure Pharma, and Actithera credited the region’s culture of straightforward communication, capital efficiency, and substance-over-hype for its outsized success in securing major pharmaceutical partnerships and institutional funding.
BioArctic CEO Gunilla Osswald highlights her company's two-decade collaboration with Japanese giant Eisai, which secured a lucrative 9% royalty rate, alongside subsequent major deals with AbbVie, Bristol Myers Squibb, Novartis, and Eli Lilly. Osswald attributed this sustained partnering success to clear internal leadership, a commitment to mutual benefit, and leveraging non-dilutive grant funding to preserve equity. AlzeCure Pharma CEO Martin Jonsson echoed this patient approach to relationship-building, which ultimately culminated in an out-licensing pact with Eli Lilly valued at over $1 billion for its Alzheimer's pipeline.
Actithera founder Andreas Goutopoulos reinforced the region's capital efficiency and data-first mentality, noting his radiopharmaceutical company secured a $75.5 million Series A by focusing entirely on scientific substance. Actithera then expanded into Oslo's dense radiopharmaceutical ecosystem, leveraging the city's concentrated academic and clinical infrastructure to become fully operational within weeks. Ultimately, these executives emphasized that Nordic biotechs are outcompeting global peers by focusing on delivering promises.
Novo Nordisk to partner with Anthropic to implement Claude Science for AI-accelerated R&D
Novo Nordisk will collaborate with Anthropic to deploy frontier AI models, including Claude Science, across Novo’s scientific research workflows to tackle complex biological reasoning and advance human drug mechanics.
Novo’s researchers will test Anthropic's models on targeted scientific workflows to improve drug target identification, analyze complex biological data, and enhance understanding of disease mechanisms. The initiative expands upon Novo's ongoing use of Claude to automate trial report generation, dramatically compressing patient documentation timelines from months to minutes.
This alliance marks Novo Nordisk's third major tech partnership of the year, following enterprise-wide agreements with OpenAI and Amazon Web Services (AWS), as CEO Mike Doustdar works toward positioning Novo as the world's most AI-driven healthcare company.
